Blue Earth Therapeutics will leverage Shine's non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials
Earth Therapeutics "Sole Food" Foot Therapy Kit dealgenius.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealgenius.com Daily Mail and Mail on Sunday newspapers.
Blue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that it will be presenting at the upcoming B. Riley Securities' Radiopharma Investor.
– First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1 –– 177Lutetium-labeled radiohybrid (rh) Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is now in clinical development as a highly optimized, next ge.